23 Feb Cabaletta Bio
Steven Nichtberger, M.D., Co-Founder and CEO
Philadelphia, PA
(NASDAQ: CABA)
Virtual Presentation
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta’s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells. The company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase I clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The U.S. Food and Drug Administration (FDA) granted Fast Track Designation for DSG3-CAART in May 2020. The company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
